On October 2, HBM HOLDINGS-B declined 5.34% in regular trading, trading at HK$12.98/share, with turnover of HK$13.86 million. The stock pulled back alongside a broad sell-off across the biotechnology sector.

Within the Biotechnology sector where HBM HOLDINGS-B belongs, individual stocks were broadly under pressure. Among peers, BEONE MEDICINES fell 6.83%, 3SBIO fell 5.85%, SKB BIO fell 5.50%, INNOVENT BIO fell 4.74%, and AKESO fell 4.14%. The sector-wide weakness weighed on HBM HOLDINGS-B despite a series of recent positive developments, including its subsidiary Nona Biosciences launching the globally first fully human heavy-chain antibody language model HCAbLM, positive Phase II interim data for its ultra-long-acting TSLP antibody HBM9378/WIN378 in asthma with Phase III initiation, and solid first-half revenue of US$122 million representing 20.9% year-over-year growth with a gross margin of 95.24%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)